Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 9/20 | 0.68 |
| ▸ | CCKBR | P32239 | 1/20 | 0.68 |
| ▸ | ECE1 | P42892 | 1/20 | 0.68 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.68 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.67 |
| ▸ | PTH1R | Q03431 | 7/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.63 |
| ▸ | GCGR | P47871 | 1/20 | 0.63 |
| ▸ | GIPR | P48546 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595353 | 0.94 | GLP1R (0.67) | GLP1RCCKBRECE1MUS81PTH1R | |
| SCHEMBL29594176 | 0.93 | RXFP1 (0.69) | GLP1RCCKBRECE1MUS81IL23R | |
| SCHEMBL31694503 | 0.93 | PTH1R (0.72) | GLP1RCCKBRECE1MUS81IL23R | |
| SCHEMBL29595673 | 0.93 | GLP1R (0.64) | GLP1RCCKBRECE1MUS81IL23R | |
| SCHEMBL29594048 | 0.91 | GLP1R (0.62) | GLP1RCCKBRECE1MUS81PTH1R | |
| SCHEMBL31000919 | 0.91 | GLP1R (0.76) | GLP1RCCKBRECE1MUS81IL23R | |
| SCHEMBL29429591 | 0.91 | GLP1R (0.76) | GLP1RCCKBRECE1MUS81PTH1R | |
| SCHEMBL29365074 | 0.90 | GLP1R (0.65) | GLP1RCCKBRECE1MUS81IL23R | |
| SCHEMBL29595296 | 0.90 | GLP1R (0.64) | GLP1RCCKBRECE1MUS81PTH1R | |
| SCHEMBL29595262 | 0.90 | GLP1R (0.64) | GLP1RCCKBRECE1MUS81PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312756-B2 | Engineered potent cytotoxic stapled BH3 peptides | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-04-26 | — | — | US | claimed |
| US-11312756-B2 | Engineered potent cytotoxic stapled BH3 peptides | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312756-B2 | Engineered potent cytotoxic stapled BH3 peptides | BID, MCL1, BCL2L13 | GLP1R 286/4885CCKBR 669/4885ECE1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.